Emend®

Merck & Co., Inc. (USA)

Anti-nausea drug for chemotherapy patients that contains “80 or 125 mg of aprepitant formulated as NanoCrystal drug particles”
“NanoCrystal particles are small particles of drug substance, typically less than 1000 nanometers (nm) in diameter, which are produced by milling the drug substance using a proprietary, wet-milling technique. The NanoCrystal particles of the drug are stabilized against agglomeration by surface adsorption of selected GRAS (Generally Regarded As Safe) stabilizers. The result is an aqueous dispersion of the drug substance that behaves like a solution – a NanoCrystal colloidal dispersion, which can be processed into finished dosage forms for all routes of administration.”
Approved by the FDA in March 2003, commercially launched in the United States in April 2003